About Us
Science
Pipeline
- HMBD-001
- HMBD-501
News
Partnering
Patients
Contact
Join Us

AAI Immunology 2023: Targeting pathogenic auto-reactive VH4-34 B cells with a rationally developed and highly specific anti-VH4-34 antibody offers a new therapeutic approach for VH4-34 autoimmune disorders

by communications@hummingbirdbio.com on 18 May, 2023 in HMBD-011, Posters, Posters - 2023, Publications & Posters

<< Back to Publications

AAI Immunology 2023: Targeting pathogenic auto-reactive VH4-34 B cells with a rationally
developed and highly specific anti-VH4-34 antibody offers a new
therapeutic approach for VH4-34 autoimmune disorders

18 May, 2023

2023-May-09 - AAI Immunology Poster - vF

VIEW POSTER

<< Back to News

PubPosts-HMBD-011 RelatedNews-HMBD-011

Previous Reading

Hummingbird Bioscience and Merck Enter Collaboration to Evaluate HMBD-001 In Squamous Non-Small Cell Lung Carcinoma

Next Reading

Hummingbird Bioscience Announces HMBD-002 Trials in Progress Poster at ASCO Annual Meeting 2023

Subscribe to our updates

*indicates required

*Email Address

*First Name

*Last Name

*Company

You can unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please visit our website. For questions about this mailing list, please email communications@hummingbirdbio.com

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.

AAI Immunology 2023: Targeting pathogenic auto-reactive VH4-34 B cells with a rationally developed and highly specific anti-VH4-34 antibody offers a new therapeutic approach for VH4-34 autoimmune disorders

AAI Immunology 2023: Targeting pathogenic auto-reactive VH4-34 B cells with a rationally developed and highly specific anti-VH4-34 antibody offers a new therapeutic approach for VH4-34 autoimmune disorders

Leave a Reply Cancel reply

AAI Immunology 2023: Targeting pathogenic auto-reactive VH4-34 B cells with a rationally
developed and highly specific anti-VH4-34 antibody offers a new
therapeutic approach for VH4-34 autoimmune disorders